{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:46:55Z","timestamp":1770472015384,"version":"3.49.0"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2470,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,10,2]]},"abstract":"<jats:sec><jats:title>Introduction:<\/jats:title><jats:p>Infliximab is an established treatment for steroid\u2010resistant and fistulating Crohn\u2019s disease. Although efficacy has been shown in clinical trials, financial implications often limit its use and limited data exist regarding clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims:<\/jats:title><jats:p>To audit the clinical effectiveness of Infliximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We prospectively audited 50 consecutive patients [28 females; median age, 34\u2003years (17\u201370\u2003years)]. Disease activity and response rates were assessed by the Harvey\u2013Bradshaw index. Clinical and disease data were collected and blood was taken for inflammatory markers, complement and double\u2010stranded DNA antibodies. Patients received Infliximab at 5\u2003mg\/kg and were followed for 12\u2003weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Indications for Infliximab were refractory Crohn\u2019s disease in 39 patients, fistulating Crohn\u2019s disease in six, pyoderma gangrenosum in one, pouchitis in two and coeliac disease in two. Thirty\u2010one (79%) of the refractory Crohn\u2019s disease patients and four (66%) of the fistulating patients responded at 4\u2003weeks. Twenty\u2010one (54%) of the refractory Crohn\u2019s disease patients had a continued response at 12\u2003weeks. Perianal disease was more prevalent in non\u2010responders (7\/8 vs. 12\/31, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Response rates to Infliximab in our group are comparable to those of clinical trials. Despite the expense, it remains a useful adjunct to treatment in this otherwise difficult group of patients. Patients with perianal disease responded less well in our cohort.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01092.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:10Z","timestamp":1047354190000},"page":"1639-1646","source":"Crossref","is-referenced-by-count":57,"title":["Clinical use of Infliximab in Crohn\u2019s disease: the Edinburgh experience"],"prefix":"10.1111","volume":"15","author":[{"given":"I. D. R.","family":"Arnott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70005-3"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03363.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","article-title":"Clinical experience with infliximab therapy in 100 patients with Crohn\u2019s disease","volume":"95","author":"Farrell RJ","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03612.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.135.5.564"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1999.0029900429"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105948"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8780559"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03325.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003840100285"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.3780010206"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(76)80163-1"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199703000-00004"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200105000-00001"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02049839"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70382-8"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.229"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.6.811"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02349.x"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90277-5"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01092.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01092.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01092.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:05:10Z","timestamp":1697537110000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01092.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,2]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10,2]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01092.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01092.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,2]]}}}